KDNY Chinook Therapeutics Inc

Chinook Therapeutics to Present at Upcoming Investor Conferences

Chinook Therapeutics to Present at Upcoming Investor Conferences

SEATTLE , April 27, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in the following upcoming investor conferences:

  • H.C. Wainwright BioConnect Investor Conference – Fireside chat on Tuesday, May 2nd at 9:30 am EDT



  • Bank of America Securities Healthcare Conference 2023 – Fireside chat on Wednesday, May 10th at 2:20 pm EDT

To access the audio webcasts and subsequent archived recording of these and other company presentations, please visit the  section of Chinook’s website. The archived audio webcasts will remain available for replay on Chinook’s website for 90 days.

About Chinook Therapeutics, Inc.

Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases. Chinook’s product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook’s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody, is being evaluated in a phase 1/2 trial for IgA nephropathy. CHK-336, an oral small molecule LDHA inhibitor for the treatment of hyperoxalurias, is in phase 1 development. In addition, Chinook’s research and discovery efforts are focused on building a pipeline of precision medicines for rare, severe chronic kidney diseases with defined genetic and molecular drivers. Chinook is leveraging insights from kidney single cell RNA sequencing and large CKD patient cohorts that have been comprehensively panomically phenotyped, with retained biosamples and prospective clinical follow-up, to discover and develop therapeutic candidates with mechanisms of action targeted against key kidney disease pathways. To learn more, visit .



Contact:
Noopur Liffick
Senior Vice President, Investor Relations & Corporate Communications
 
 
EN
27/04/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Chinook Therapeutics Inc

 PRESS RELEASE

Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase...

Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 BEYOND Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy SEATTLE, July 28, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the first patient with IgA nephropathy (IgAN) has been enrolled in the BEYOND study, a pivotal phase 3 clinical trial evaluating the safety and efficacy of zigakibart (BION-1301), a potentially disease-modifyin...

 PRESS RELEASE

Chinook Therapeutics Presents Data from CHK-336 Phase 1 Trial in Healt...

Chinook Therapeutics Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failed Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) Congress CHK-336 was generally well tolerated in healthy volunteers (HV) who received single doses up to 500 mg and multiple doses up to 60 mg for 14 daysPharmacokinetics (PK) was well characterized with dose-proportional exposures and a half-life that supports once-daily dosingSuccessful implementation of a novel 13C2-glycolate tracer established proof-of-mechanism of CHK-336 to block hepat...

 PRESS RELEASE

Chinook Therapeutics to Present Updated Data from Zigakibart (BION-130...

Chinook Therapeutics to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) at the 60th European Renal Association (ERA) Congress Zigakibart treatment continues to demonstrate rapid and sustained reductions in mechanistic biomarkers, including IgA and Gd-IgA1 levels, which correspond to clinically meaningful proteinuria reductions in patients with IgAN across Cohorts 1 and 2Zigakibart is well-tolerated, with no ADAs observed or treatment discontinuations due to adverse events (AEs) in patients with IgAN across Cohorts 1 and 2 In all patie...

 PRESS RELEASE

Chinook Therapeutics Enters into Agreement to be Acquired by Novartis ...

Chinook Therapeutics Enters into Agreement to be Acquired by Novartis AG Novartis to acquire Chinook for $40 per share in cash, with potential to receive up to an additional $4 per share in cash through contingent value rights, for a total equity value of up to approximately $3.5 billionChinook’s diversified pipeline of potentially best-in-class programs for rare, severe chronic kidney diseases will significantly expand the Novartis renal portfolio, complementing its existing pipelineTransaction expected to be completed in the second half of 2023, subject to customary closing conditions ...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

PX Forming Coiled Spring Between 4200 and 4050 We continue believe that upside is limited with the S&P 500 testing the top-end of our anticipated 2023 trading range (4165-4200). Our gameplan remains unchanged; reduce risk near resistance (where we are now) and add risk near support (the December 2022 lows at 3765 and/or the 2022 lows at 3490). Therefore, we continue to recommend a tactical overweight to defensives (Consumer Staples, Utilities, Health Care, and gold miners). A break above 4200 o...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch